Janux Therapeutics Inc (NASDAQ:JANX) price on Friday, August 02, fall -6.51% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $38.76.
A look at the stock’s price movement, the close in the last trading session was $41.46. Turning to its 52-week performance, $65.60 and $5.65 were the 52-week high and 52-week low respectively. Overall, JANX moved 0.68% over the past month.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Janux Therapeutics Inc’s market cap currently stands at around $2.01 billion.
The average forecast suggests down to a -27.20% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 3.72M, representing a -54.00% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that JANX is a 50% Sell. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
JANX’s current price about -9.95% and -10.95% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 39.93, while 7-day volatility ratio is 5.82% and 6.96% in the 30-day chart. Further, Janux Therapeutics Inc (JANX) has a beta value of 3.57, and an average true range (ATR) of 2.86.
If we refocus on Janux Therapeutics Inc (NASDAQ:JANX), historical trading data shows that trading volumes averaged 776.75K over the past 3 months. The company’s latest data on shares outstanding shows there are 46.25 million shares.
The 32.07% of Janux Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 73.29% of the company’s shares. Current price change has pushed the stock 261.23% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the JANX stock continues to rise going into the next quarter.
